Vertex Pharmaceuticals Finite-Lived Intangible Assets, Accumulated Amortization increased by 12.4% to $51.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 78.0%, from $29.10M to $51.80M. This increase may warrant attention — for this metric, lower values are generally preferred.
A rising balance relative to gross assets indicates an aging portfolio of intangible assets nearing the end of their useful lives.
The cumulative amount of amortization expense recognized against finite-lived intangible assets since their acquisition...
Standard accounting metric; peers with older acquisition cycles will show higher accumulated amortization relative to gross assets.
other_finite_lived_intangible_assets_accumulated_amortization| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $23.40M | $29.10M | $34.80M | $40.50M | $46.10M | $51.80M |
| QoQ Change | — | +24.4% | +19.6% | +16.4% | +13.8% | +12.4% |
| YoY Change | — | — | — | — | +97.0% | +78.0% |